CI-1020
CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 162256-50-0
- Fòrmula: C28H26O9
- Peso molecular:506.50
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
ETA 0.3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | IC50 |
120 nM
Compound: 1, (PD-156707)
|
Inhibition of Endothelin B receptor mediated (ET-3) release of arachidonic acid from human cloned receptors / CHO-K1 cells
Inhibition of Endothelin B receptor mediated (ET-3) release of arachidonic acid from human cloned receptors / CHO-K1 cells
|
[PMID: 9089328] |
| CHO-K1 | IC50 |
480 nM
Compound: 1, (PD-156707)
|
Binding affinity for human endothelin B receptor expressed in CHO-K1 cells.
Binding affinity for human endothelin B receptor expressed in CHO-K1 cells.
|
10.1016/S0960-894X(97)00002-4 |
| CHO-K1 | IC50 |
780 nM
Compound: 1, (PD-156707)
|
Binding affinity against human cloned Endothelin B receptor expressed in CHO-K1 cells
Binding affinity against human cloned Endothelin B receptor expressed in CHO-K1 cells
|
[PMID: 9089328] |
CI-1020 (40 mg/kg, p.o.) attenuates established pulmonary hypertension in rats previously exposed to chronic hypoxia[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:normal rats [2]
-
Dosage:30 mg/kg
-
Administration:oral administration (p.o.)
-
Result:Inhibited the ET-A and has no significant effect on basal blood pressure in normotensive rats.
-
Animal Model:basal blood pressure in normotensive rats[4]
-
Dosage:40 mg/kg/day
-
Administration:oral administration (p.o.)
-
Result:Reduced the increase in RV/LV+S and the percentage DEL induced by chronic hypoxia.
Lowered the increase in pulmonary resistance in isolated perfused lungs significantly.
Chemical Information
-
No. CAS 162256-50-0
-
Peso molecular 506.50
-
Fòrmula C28H26O9
-
SMILES
O=C1OC(C2=CC=C(OC)C=C2)(O)C(CC3=CC(OC)=C(OC)C(OC)=C3)=C1C4=CC=C(OCO5)C5=C4
-
Synonyms
PD156707
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Maguire JJ, et al. ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clin Sci (Lond). 2002 Aug;103 Suppl 48:184S-188S. [Content Brief]
[2]. Doherty AM, et al. Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Pharm Biotechnol. 1998;11:81-112. [Content Brief]
[3]. Jones RD, et al. The effect of the endothelin ET(A) receptor antagonist CI-1020 on hypoxic pulmonary vasoconstriction. Eur J Pharmacol. 1999 Jun 25;374(3):367-75. [Content Brief]
[4]. Sheedy W, et al. The effect of the ETA receptor antagonist (CI-1020) in rats with established hypoxic pulmonary hypertension. Pulm Pharmacol Ther. 1998 Apr-Jun;11(2-3):173-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CI-1020 Related Classifications
HY-103459 Related Classifications
Powered by Bioz